TheraRadar
← Back
Data updated: Jun 28, 2026

OCULAR THERAPEUTIX

Pharma
OphthalmologyCardiovascular Execution: Good

OCULAR THERAPEUTIX is a pharmaceutical company focused on Ophthalmology, Cardiovascular. Key products include DEXTENZA.

2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

OCULAR THERAPEUTIX at a Glance

  • Fast trial execution (12 months median completion)

OCULAR THERAPEUTIX's Key Drugs

OCULAR THERAPEUTIX's core commercial portfolio centers on DEXTENZA, spanning Ophthalmology and Cardiovascular — its most strategically important drugs approved in the last 15 years.

DEXTENZA
Ophthalmology

Ocular Inflammation

Approved 2018

OCULAR THERAPEUTIX's Recent FDA Approvals

New NDA/BLA approvals for OCULAR THERAPEUTIX over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

OCULAR THERAPEUTIX's Therapeutic Areas

OCULAR THERAPEUTIX's approved drugs and pipeline span 2 therapeutic areas, led by Ophthalmology and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Ophthalmology 81%
1 drugs Phase 3: 8 Phase 2: 6 Phase 1: 5
Cardiovascular 19%
0 drugs Phase 3: 2 Phase 2: 2 Phase 1: 1

OCULAR THERAPEUTIX's Top Competitors

OCULAR THERAPEUTIX's closest competitors by therapeutic-area and drug-target overlap include Novartis, Bayer, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma
Cardiovascular, Ophthalmology
Bayer big-pharma
Cardiovascular, Ophthalmology
B BRAUN specialty
Ophthalmology, Cardiovascular
BAUSCH specialty
Ophthalmology, Cardiovascular
BAUSCH AND LOMB INC other
Ophthalmology, Cardiovascular

OCULAR THERAPEUTIX Pipeline Snapshot

OCULAR THERAPEUTIX has 24 active clinical programs from ClinicalTrials.gov — 10 Phase 3, 8 Phase 2 and 6 Phase 1.

10
Phase 3
8
Phase 2
6
Phase 1

Phase 3 Readout Calendar Pro

3 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q1 2027
OTX-TKI
Neovascular Age-related Macular Degeneration
Estimated · stale NCT06495918
Q1 2027
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24
Non-Proliferative Diabetic Retinopathy
Estimated · fresh NCT07235085
Q3 2030
OTX-TKI
Neovascular Age-Related Macular Degeneration (nAMD)
Estimated · fresh NCT07516132

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • DEXTENZA leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Ophthalmology pipeline focus
  • • 3 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 10/14 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges